The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates

Rheumatology Drug Updates

November 1, 2013 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates
Explore This Issue
November 2013
Also By This Author
  • Sirukumab Approval Stalls
Drug Updates

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Drug Updates
Healthcare providers need to explain to caregivers and patients how to appropriately store and dispose of these patches and other potentially hazardous medications to prevent inadvertent harm, especially to very young individuals.

Pipeline and Drug Approvals

Buprenorphine transdermal system (Butrans) for treating moderate to severe chronic pain requiring a continuous, around-the-clock opioid analgesic for an extended period, has been approved by the Food and Drug Administration (FDA) in a new dosage strength of 15 μg/hour.1 It is a once-weekly transdermal patch which is already available in 5-, 10-, and 20-mcg/hr strengths. A Risk Evaluation and Mitigation Strategy (REMS) also exists for the buprenorphine transdermal system.

Canakinumab (Ilaris) has been approved by the European Commission (EC) to treat active systemic juvenile idiopathic arthritis (sJIA) in patients two years of age and older who have had an inadequate response to previous therapy with systemic corticosteroids and nonsteroidal antiinflammatory drugs (NSAIDs).2 Patients two to 19 years of age in the clinical trials showed significant improvements (84%) in the adapted pediatric ACR30 compared to a 10% response in placebo-treated patients following one subcutaneous (SubQ) dose of canakinumab. Ninety-two of 128 patients attempted steroid tapering in the open-label part of one of the studies. Of these patients, 46% discontinued corticosteroids entirely while 62% significantly reduced their corticosteroid use. Additionally, in the controlled portion of this study, there was a 64% relative reduction in the flare risk for the canakinumab-treated patients compared with placebo-treated patients. All primary endpoints were met.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ustekinumab (Stelara), the interleukin 12 and 23 antagonist, has been FDA approved for treating adults with moderate to severe psoriatic arthritis, either as monotherapy or in combination with methotrexate.3,4 This approval was based on the results of the PSUMMIT I and PSUMMIT II trials. These studies were multinational, phase III, multicenter, double-blind, placebo controlled, and randomized. Studies included 927 patients with at least five tender and swollen joints and elevated C-reactive protein (>3 mg/L) despite conventional therapy and/or previous biologic treatment with tumor necrosis factor–blocking agents. Patients received either SubQ placebo, SubQ ustekinumab 45 mg, or SubQ ustekinumab 90 mg at baseline and after one month, and every 12 weeks thereafter. Patients were randomized in a 1:1:1 manner. The primary endpoint was a 20% or greater improvement in ACR20 criteria at Week 24. In PSUMMIT 1, at six months, 42% of patients the ustekinumab 45 mg–treated group had a 20% improvement in symptoms, according to the ACR20; 50% of the ustekinumab 90 mg–treated group had a 20% improvement in symptoms, according to the ACR20 in the same timeframe. Placebo-treated patients had a 23% response rate. In PSUMMIT II, 44% of active-treated patients had an ACR20 response at six months.

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates, Safety Tagged With: Drugs, FDA, rheumatology, SafetyIssue: November 2013

You Might Also Like:
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates
  • Hepatitis Reaction with Rituximab Sparks Drug Safety Alert

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)